Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025

Core Insights - Cognition Therapeutics, Inc. will present biomarker results from the Phase 2 SHINE study of zervimesine (CT1812) for Alzheimer's disease at the AD/PD 2025 Conference [1] - The study focuses on key proteins, or biomarkers, associated with Alzheimer's disease progression, including neurofilament light (NfL), glial fibrillary acidic protein (GFAP), amyloid beta (Aβ), and tau species [2] - The analysis aims to provide insights into the impact of zervimesine on disease biology by comparing biomarker changes in participants receiving the drug versus those on placebo [3] Presentation Details - The podium presentation titled "Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients" is scheduled for April 1, 2025, at 2:45 PM CET [4] - Additional poster presentations will cover CSF proteomic biomarker analysis, identification of CSF proteins correlating with cognitive outcomes, and molecular correlates with treatment-related decreases in NfL CSF levels [4] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders [5] - The lead candidate, zervimesine (CT1812), is being investigated in clinical programs for dementia with Lewy bodies and Alzheimer's disease, including the ongoing START study [5] - The company believes zervimesine can regulate impaired pathways in these diseases through its interaction with the sigma-2 receptor, which is distinct from other treatment approaches [5]